Dr. Modesitt is the Director of the Gynecologic Oncology Division and the Co-Director of the High Risk Breast/Ovarian Cancer clinic at the University of Virginia. She is an Associate Professor and the Richard and Louise Crockett endowed Chair in Obstetrics and Gynecology. She completed her residency at the University of North Carolina and her fellowship at the M.D. Anderson Cancer Center. Dr. Modesitt served the Society of Gynecologic Oncology as Vice Chair of the Practice Survey Task force, Chair of the Candidate Task force and an Education Committee member. She was appointed to the Prolog Task force and Gynecologic Oncology Subcommittee for the American College of Obstetricians and Gynecologists. Dr. Modesitt is the UVA PI for the Gynecologic Oncology Group and is on the Safety Review and Developmental Therapeutics committees. Her research focuses on obesity related cancers, clinical trials and hereditary cancers.
Visit the Sisterhood of Survivorship page to read “Dena’s Story” — by a vulvar cancer survivor who has shared her story and wise words, and channeled her energy into her National Race to End Women’s Cancer team.
Vaccine efficacy against vulvar infection with HPV 16/18 was comparable to the efficacy found against cervical infection 4 years after vaccination, according to researchers with the National Cancer Institute.
The Foundation has published its 2014-2015 Research Grants and Awards Booklet with Applications. Please consider applying to become part of an elite group of physician-scientists committed to the well-being of women at risk for/affected by gyn malignancies.